Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024 16:00 ET
|
Molecular Partners
Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive...
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
December 14, 2023 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
December 10, 2023 12:00 ET
|
Molecular Partners
Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported...
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
November 14, 2023 01:00 ET
|
Molecular Partners
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review...
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
November 03, 2023 12:00 ET
|
Molecular Partners
MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the...
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
November 02, 2023 02:00 ET
|
Molecular Partners
MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to...
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
November 01, 2023 02:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
October 26, 2023 16:00 ET
|
Molecular Partners
MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting...
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
September 13, 2023 01:00 ET
|
Molecular Partners
New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad...
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
August 24, 2023 16:00 ET
|
Molecular Partners
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected...